Editorial: New insight into the diagnosis and treatment of age-related macular degeneration

Editorial: New insight into the diagnosis and treatment of age-related macular degeneration

Bibliographic Details
Main Authors:	Andrea Servillo, Riccardo Sacconi, Giuseppe Querques
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Medicine
Subjects:	age-related macula degeneration anti-vascular endothelial growth factor neovascularization treatment diagnosis
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.993349/full

Similar Items

Optical Coherence Tomography Angiography: A 2023 Focused Update on Age-Related Macular Degeneration
by: Beatrice Tombolini, et al.
Published: (2024-01-01)

Shedding Light on Photobiomodulation Therapy for Age-Related Macular Degeneration: A Narrative Review
by: Federico Fantaguzzi, et al.
Published: (2023-09-01)

Autophagy Genes for Wet Age-Related Macular Degeneration in a Finnish Case-Control Study
by: Jussi J. Paterno, et al.
Published: (2020-11-01)

Editorial: Retinal vascular functional assessment in health and disease
by: Andrea Servillo, et al.
Published: (2022-09-01)

Artificial intelligence in age-related macular degeneration: state of the art and recent updates
by: Emanuele Crincoli, et al.
Published: (2024-03-01)

Optical Coherence Tomography Angiography Parameters Correlated to the Growth of Macular Neovascularization in Age-Related Macular Degeneration
by: Alessandro Arrigo, et al.
Published: (2022-05-01)

Subclinical Angioid Streaks with Pseudodrusen: A New Phenotype of Age-Related Macular Degeneration
by: Riccardo Sacconi, et al.
Published: (2023-08-01)

Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
by: Federico Ricci, et al.
Published: (2020-11-01)

Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy
by: Nair AA, et al.
Published: (2022-09-01)

Current advance in the application of anti-vascular endothelial growth factor drugs in wet age-related macular degeneration
by: Ling-Yi Ouyang, et al.
Published: (2020-01-01)

No-Dose Photodynamic Therapy Against Half-Dose Photodynamic Therapy for Treatment of Central Serous Chorioretinopathy
by: Andrea Servillo, et al.
Published: (2023-06-01)

Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
by: Mine Esen Barış, et al.
Published: (2020-10-01)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016-06-01)

Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration
by: Oluchukwu Onwuka, et al.
Published: (2023-01-01)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
by: Almeida DRP, et al.
Published: (2021-01-01)

A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK
by: Hykin P, et al.
Published: (2016-01-01)

Study of optical coherence tomography angiography for neovascular age-related macular degeneration
by: Xiao-Xue Min, et al.
Published: (2018-12-01)

Analyses of the effects of persistent subretinal fluid on visual/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients
by: Kyung Tae Kim, et al.
Published: (2021-08-01)

Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate
by: Brice Nguedia Vofo, et al.
Published: (2023-05-01)

Optimal approaches and criteria to treat-and-extend regimen implementation for Neovascular age-related macular degeneration: experts consensus in Taiwan
by: Cheng-Kuo Cheng, et al.
Published: (2022-01-01)

Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
by: Janusz Blasiak, et al.
Published: (2023-07-01)

Vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in an Egyptian population
by: Marwa Abdel Kareem Mohamed Aly, et al.
Published: (2023-01-01)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
by: Leung EH, et al.
Published: (2023-05-01)

Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration
by: Murat Karaçorlu, et al.
Published: (2019-10-01)

XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
by: Jean-François Korobelnik, et al.
Published: (2024-01-01)

Progress in the treatment of neovascular age-related macular degeneration
by: Ya-Xin Wang, et al.
Published: (2021-10-01)

OCTA in evaluating therapeutic effect of wet age-related macular degeneration
by: Liang Wang, et al.
Published: (2020-06-01)

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration
by: Shaikh Saad, et al.
Published: (2007-01-01)

Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration
by: Kaiqin She, et al.
Published: (2022-03-01)

Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
by: Levon M. Khachigian, et al.
Published: (2023-02-01)

Discontinuation of treatment and retreatment of neovascular age-related macular degeneration in the real-world: Bundang AMD cohort study report 5
by: Soo Chang Cho, et al.
Published: (2023-07-01)

Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration
by: Javier Zarranz-Ventura, et al.
Published: (2023-07-01)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
by: Cheema MR, et al.
Published: (2021-01-01)

VEGF Inhibition Associates With Decreased Risk of Mortality in Patients With Neovascular Age-related Macular Degeneration
by: Benjamin Sommer Thinggaard, MD, et al.
Published: (2024-05-01)

Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome
by: Raúl Martínez-Castillo, et al.
Published: (2023-04-01)

Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration
by: Li W, et al.
Published: (2016-10-01)

Elevated YKL‐40 serum levels may contribute to wet age‐related macular degeneration via the ERK1/2 pathway
by: Yue Bin, et al.
Published: (2021-11-01)

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)
by: Prem Patel, et al.
Published: (2021-05-01)

Introduction, mechanism of action and rationale for anti-vascular endothelial growth factor drugs in age-related macular degeneration
by: Kim Ramasamy
Published: (2007-01-01)

Subclinical Ocular Changes after Intravitreal Injections of Different Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Hisashi Matsubara, et al.
Published: (2023-11-01)